# Advances in Understanding Renin–Angiotensin System-Mediated Anti-Tumor Activity of Natural Polyphenols

**Authors:** Ximing Wu, Mingchuan Yang, Hailing Zhang, Lumin Yang, Yufeng He, Xiaozhong Cheng, Guilan Zhu

PMC · DOI: 10.3390/biom15111541 · 2025-11-02

## TL;DR

This review explores how natural polyphenols fight cancer by balancing the renin–angiotensin system and highlights challenges and solutions for their use.

## Contribution

The paper introduces the dual-regulation of RAS by polyphenols and their autoxidation products as a novel anti-cancer mechanism.

## Key findings

- Polyphenols inhibit the pro-tumor ACE/AngII/AT1R axis while activating the protective ACE2/Ang(1-7)/MasR axis.
- EAOP, a polyphenol oxidation product, shows stronger RAS-modulating effects than the original polyphenols.
- Polyphenols disrupt oncogenic pathways like MAPK and PI3K/Akt/mTOR, reducing tumor growth and oxidative stress.

## Abstract

The imbalance of the renin–angiotensin system (RAS), characterized by the overactivation of the pro-tumor ACE/AngII/AT1R axis, is closely linked to tumor growth, angiogenesis, metastasis, and poor prognosis. Natural polyphenols, such as EGCG and resveratrol, exert anti-cancer effects by dual-regulating RAS: they inhibit the pro-tumor axis by blocking renin, ACE activity, and AT1R expression, while simultaneously activating the protective ACE2/Ang(1-7)/MasR axis. Furthermore, polyphenols and their autoxidation products (e.g., EAOP) modify thiol-containing transmembrane proteins (such as ADAM17 and integrins) and interact with RAS components, further disrupting oncogenic pathways (including MAPK and PI3K/Akt/mTOR) to induce apoptosis, suppress invasion, and reduce oxidative stress. Notably, EAOP exhibits stronger RAS-modulating efficacy than its parent polyphenols. However, challenges such as low bioavailability, insufficient targeting, and limited clinical evidence impede their application. This review provides a comprehensive overview of the anti-cancer mechanisms of polyphenols through RAS regulation, discusses the associated challenges, and proposes potential solutions (including nanodelivery and structural modification) and strategies to advance natural product-based adjuvant treatments.

## Linked entities

- **Proteins:** PLEKHA6 (pleckstrin homology domain containing A6), ACE (angiotensin I converting enzyme), AGTR1 (angiotensin II receptor type 1), ACE2 (angiotensin converting enzyme 2), Mas1 (MAS1 proto-oncogene, G protein-coupled receptor), ADAM17 (ADAM metallopeptidase domain 17), ITGB1 (integrin subunit beta 1)
- **Chemicals:** EGCG (PubChem CID 65064), resveratrol (PubChem CID 5056)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** ADAM17 (ADAM metallopeptidase domain 17) [NCBI Gene 6868] {aka ADAM18, CD156B, CSVP, HYPT16, NISBD, NISBD1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, MAS1L (MAS1 proto-oncogene like, G protein-coupled receptor) [NCBI Gene 116511] {aka MAS-L, MRG, dJ994E9.2}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}
- **Diseases:** metastasis (MESH:D009362), Tumor (MESH:D009369)
- **Chemicals:** resveratrol (MESH:D000077185), EAOP (-), Polyphenols (MESH:D059808), EGCG (MESH:C045651), thiol (MESH:D013438)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12650386/full.md

---
Source: https://tomesphere.com/paper/PMC12650386